Literature DB >> 10652623

Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.

V Zolota1, A Gerokosta, M Melachrinou, A Kominea, C Aletra, C D Scopa.   

Abstract

BACKGROUND: Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of lesions that show important differences in biologic behavior. New vessel formation has been reported as a prognostic indicator in breast carcinoma, but little information is available about its significance in DCIS. This study was planned to examine angiogenesis in DCIS in relation to histologic subtype, proliferation activity, p53 and bcl-2 expression.
MATERIALS AND METHODS: Paraffin sections from 24 cases of DCIS (9 comedo and 15 non comedo type) were studied immunohistochemically using polyclonal and monoclonal antibodies to von Willebrand factor, Ki-67, p53 (clone 1801) and bcl-2 proteins. The streptavidine-biotin technique with microwave antigen retrieval was employed.
RESULTS: Most cases showed enhanced microvessel formation around ducts with DCIS compared to normal ducts. Comedo carcinomas (CCs) showed enhanced neovascularization compared to non comedo carcinomas (NCCs). Growth fraction determination with Ki-67 antibody showed that 78% of the CCs expressed high proliferating activity compared to 27% of the NCCs. p53 immunoexpression was noted in 78% of the CCs and 20% of the NCCs. Bcl-2 immunoreactivity was observed in 67% of the total cases in 58% of which there was no association with p53 expression. However, an association was found between neovascularization and overexpression of Ki-67 and p53.
CONCLUSIONS: This study suggests that neovascularization is an early phenomenon in breast neoplasia and is apparent as early as the in situ stage. CCs express a more aggressive immunophenotype, compared to the other DCIS subtypes, characterized by increased stromal interaction, high proliferating activity, p53 overexpression and a near lack of bcl-2 immunostaining.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10652623

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

2.  Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma.

Authors:  Min-Hua Sun; Xi-Chun Han; Ming-Ku Jia; Wei-Dong Jiang; Min Wang; Hong Zhang; Gang Han; Yi Jiang
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

3.  Relationship between PTEN and VEGF expression and clinicopathological characteristics in HCC.

Authors:  Denghai Mi; Jilin Yi; Enyu Liu; Xingrui Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

4.  Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.

Authors:  Tom M Ganten; Jaromir Sykora; Ronald Koschny; Emanuela Batke; Sebastian Aulmann; Ulrich Mansmann; Wolfgang Stremmel; Hans-Peter Sinn; Henning Walczak
Journal:  J Mol Med (Berl)       Date:  2009-08-13       Impact factor: 4.599

5.  Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

Authors:  H P Kourea; A K Koutras; C D Scopa; M N Marangos; E Tzoracoeleftherakis; D Koukouras; H P Kalofonos
Journal:  Mol Pathol       Date:  2003-12

6.  Naringin inhibits ovarian tumor growth by promoting apoptosis: An in vivo study.

Authors:  Liping Cai; Heli Wu; Chunhua Tu; Xiaochun Wen; Bei Zhou
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

7.  Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice.

Authors:  Mingxiang Chang; Meimei Wu; Hanmin Li
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

8.  Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer.

Authors:  E M Connolly; J H Harmey; T O'Grady; D Foley; G Roche-Nagle; E Kay; D J Bouchier-Hayes
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.